Chester County News and Community Website
WILMINGTON, DE — AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application for DATROWAY® (datopotamab deruxtecan-dlnk) has been accepted and granted Priority Review by the U.S. Food and Drug Administration for …
DATROWAY Gains Priority Review for Aggressive Breast Cancer Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported its first unconfirmed partial response in a Phase 1 study of its experimental cancer drug APR-1051, an early signal the company …
Early Cancer Signal Emerges as Aprea Drug Shrinks Tumors in Phase 1 Trial Read More
NEWARK, DE — New preclinical research from CorriXR Therapeutics suggests a novel gene-editing strategy could reopen the door to standard chemotherapy for patients whose cancers have become resistant to treatment, …
CRISPR Breakthrough Reverses Chemo Resistance in Aggressive Cancers Read More WILMINGTON, DE — AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) said their jointly developed breast cancer therapy ENHERTU has received Breakthrough Therapy Designation from the U.S. Food and Drug …
ENHERTU Scores Tenth FDA Fast-Track as Breast Cancer Data Shifts Playbook Read More WILMINGTON, DE — AstraZeneca secured U.S. approval for its IMFINZI (durvalumab) regimen in combination with FLOT chemotherapy for early-stage and locally advanced gastric and gastroesophageal junction cancers, marking the first …
AstraZeneca Wins Landmark Approval for IMFINZI Regimen in Early Gastric Cancer Read More
WILMINGTON, DE — ChristianaCare has opened a first-of-its-kind organoid core inside a community cancer program, creating a new laboratory capable of growing patient-derived “mini tumors” to guide more precise and …
New ‘Tumor-on-a-Chip’ Lab Promises Breakthroughs for Delaware Cancer Patients Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has submitted a federal priority-review request for its investigational SkinJect microneedle patch, a dissolvable doxorubicin-based therapy designed to non-invasively treat basal cell …
Skin Cancer Breakthrough? Pharma Firm Seeks Fast-Track FDA Voucher for Novel Patch Read More
KING OF PRUSSIA, PA — SEED Therapeutics announced that China’s National Medical Products Administration has cleared the Investigational New Drug application for ST-01156, enabling Chinese sites to participate in the …
China Clears IND for SEED Therapeutics’ First-in-Class Cancer Drug in Global Trial Push Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) unveiled compelling new data from its Phase 2 study of VP-315, a first-in-class oncolytic peptide immunotherapy, showing strong local immune activation …
New Cancer Data Hints at a Surgery-Free Future — Verrica’s VP-315 Shows Big Promise Read More
PHOENIXVILLE, PA — Facet Life Sciences has entered a strategic partnership with XCancer®, a global leader in theranostic clinical research, to accelerate the development and regulatory approval of next-generation radiopharmaceutical …
Facet Life Sciences and XCancer Join Forces to Speed Cancer Therapy Approvals Read More